Sign Out
Haemophilia A with inhibitors, Haemophilia B with inhibitors
Adult: As treatment of bleeding episodes: Initially, 90 mcg/kg; additional doses may be given as necessary to achieve and maintain haemostasis, initially at 2-3 hour intervals. In patients with mild to moderate bleeding episodes (including home therapy): 90 mcg/kg for 2-3 doses given at 3-hour intervals; may give 1 additional dose if required; alternatively, 270 mcg/kg as a single dose. Max duration of home therapy: 24 hours. In patients with serious bleeding episodes: Initially, 90 mcg/kg may be given on the way to the hospital, then adjust dosing according to response. Duration of treatment: 2-3 weeks, or more if clinically indicated. In patients undergoing invasive procedure or surgery: Initially, 90 mcg/kg given immediately before the intervention; repeat dose after 2 hours, then continued at 2-3-hour intervals for the 1st 24-48 hours, depending on the intervention performed and patient’s clinical status. In major surgery: Doses are continued at 2-4-hour intervals for 6-7 days, then the interval may be increased to 6-8 hours for another 2 weeks. Treatment duration may be up to 2-3 weeks until healing has occurred. All doses are given via IV bolus inj over 2-5 minutes. Dosing interval and treatment duration may vary according to the severity of bleeding and the surgery or invasive procedures being performed. Treatment and dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Intravenous
Factor VII deficiency
Adult: As treatment of bleeding episodes or prevention of bleeding in patients undergoing surgery or invasive procedures: 15-30 mcg/kg 4-6 hourly via IV bolus inj over 2-5 minutes until haemostasis is achieved. Dosage is individualised and adjusted according to patient's clinical response. Treatment and dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Intravenous
Acquired haemophilia
Adult: As treatment for bleeding episodes or prevention of bleeding in patients undergoing surgery or invasive procedures: Initially, 90 mcg/kg via IV bolus inj over 2-5 minutes given as early as possible at the start of bleeding episode. Additional doses may be given as necessary to achieve and maintain haemostasis, initially at 2-3 hour intervals. Dosing interval and treatment duration may vary according to the severity of bleeding and the surgery or invasive procedures being performed. Treatment and dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Intravenous
Glanzmann's thrombasthenia
Adult: As treatment of bleeding episodes and prevention of bleeding in patients undergoing surgery or invasive procedures who are refractory to platelet transfusions: 90 mcg/kg 2 hourly via IV bolus inj over 2-5 minutes for at least 3 doses. Treatment and dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Intravenous
Postpartum haemorrhage
Adult: As treatment for severe cases when uterotonics are inadequate to obtain haemostasis: 60-90 mcg/kg as a single dose via IV bolus inj over 2-5 minutes. Dose may be repeated after 30 minutes if with inadequate haemostatic response. Treatment and dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
